For prognosis, high FHL2 expression was associated with poor OS in patients with THCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney renal clear cell carcinoma (KIRC), HNSC, LUAD, ovarian serous cystadenocarcinoma (OV), and LUSC. Here, FHL2 is linked to cervical squamous cell carcinoma.